The BENEFIT Trial: Where Do We Go from Here?

In the next five years, we can now project that 200,000 people living with Chagas disease will die from heart disease and related complications. We urgently need to redouble our efforts to identify and treat young people who are still in the early stages of their illness, but ultimately we need to f...

Full description

Saved in:
Bibliographic Details
Published in:PLoS neglected tropical diseases 2016-02, Vol.10 (2), p.e0004343-e0004343
Main Authors: Pecoul, Bernard, Batista, Carolina, Stobbaerts, Eric, Ribeiro, Isabella, Vilasanjuan, Rafael, Gascon, Joaquim, Pinazo, Maria Jesus, Moriana, Silvia, Gold, Silvia, Pereiro, Ana, Navarro, Miriam, Torrico, Faustino, Bottazzi, Maria Elena, Hotez, Peter J
Format: Article
Language:English
Subjects:
Antiprotozoal Agents - administration & dosage
Benznidazole
Biology and Life Sciences
Care and treatment
Chagas disease
Chagas Disease - diagnosis
Chagas Disease - drug therapy
Chagas Disease - parasitology
Chemotherapy
Clinical Trials as Topic
Diagnosis
Dosage and administration
Drug Evaluation
Heart diseases
Humans
Malaltia de Chagas
Malalties del cor
Medicine and Health Sciences
Nitroimidazoles - administration & dosage
Patient outcomes
Patients
Pharmaceutical industry
Product development
Research and Analysis Methods
Studies
Trypanosoma cruzi - drug effects
Trypanosoma cruzi - physiology
World Health Organization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the next five years, we can now project that 200,000 people living with Chagas disease will die from heart disease and related complications. We urgently need to redouble our efforts to identify and treat young people who are still in the early stages of their illness, but ultimately we need to find better treatments and new cures.
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0004343